The value of the global market for glaucoma treatments is predicted to increase to $3bn USD (£1.93bn) by 2023, according to a new report from consulting firm GlobalData.
The report, which covers seven major markets for glaucoma therapeutics – the UK, France, Germany, Italy, Spain, the US and Japan – predicts that the increase will be driven by the release of a number of new drugs and fixed-dose combinations (FDCs).
New drugs set to be released over the forecast period include Aerie pharmaceuticals’ Rhopressa and Roclatan, Bausch & Lomb and Nicox’s candidate drug, Vesneo, and Inotek pharma’s trabodenoson. While FDCs to emerge will include Santen’s Taptiqom and Alcon’s Simbrinza.
GlobalData’s senior analyst for neurology and ophthalmology, Dr Catherine Daly, said: “The six products anticipated to enter the [market] during the forecast period will collectively generate sales of $672m by 2023, constituting a 22.2% share of the global market.”
Dr Daly added: “[Aerie pharmaceuticals’] Roclatan is forecast to achieve the highest sales among these drugs, and is expected to generate approximately $262 million in 2023. Significant uptake of Roclatan in the US, due to the drug’s enviable position of becoming the first prostaglandin, analog-containing FDC product available in this large arena, will be the main overall market driver.”
However, the US market value could be negatively affected in the final two years of the forecast period as Allergan’s Combigan comes off patent in 2022, opening the door for generic FDCs.
Image credit: Andreas Poike